Affiliation:
1. V.A. Negovsky Research Institute of General Reanimatology, Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology
Abstract
The mortality rate among patients with acute suppurative lung diseases (ASLD) in the ICU reaches 30%. Early, pathogenetically relevant biomarkers are needed to ensure personification and better efficacy of ASLD treatment. Numeric variations in the counts of immune system cells in patient’s blood can be viewed as such candidate biomarkers.The aim of the study. Identification of potential markers predicting ASLD outcome after community-acquired pneumonia and COVID-19.Materials and methods. The study included 216 in-hospital patients aged 18-87 with ASLD after community-acquired pneumonia with (N=81) and without (N=135) COVID-19 history.Results. Patients survival after COVID-19 was linked to lymphocyte count on Day 1 of hospital stay (hazard ratio, HR=5.9 95%CI 0.9–37.4; P=0.0188, log-rank test). In patients who had not have COVID-19, a difference in survival was associated with lymphocyte (HR=2.9 95%CI 1.0–8.4; P=0.0184, log-rank test; N=135), and monocyte counts (HR=2.7 95% CI 0.8–9.5; P=0.0196, log-rank test) on Day 1 of hospital stay. Patients’ survival after COVID-19 infection depended on SII (systemic immune-inflammation index. HR=9.3 95%CI 1.7–49.8; P=0.0124, log-rank test; N=81, SIRI (systemic inflammatory response index, HR=7.2 95%CI 1.4–36.6; P=0.0339, log-rank test; N=81) and NLR (neutrophil-to-lymphocyte ratio, HR=9.6 95%CI 1.8–52.0; P=0.0108; log-rank test; N=81) values on Day 1 of hospital stay. In patients who did not have COVID-19 SII values had no influence on survival.Conclusion. The lymphocyte count makes it possible to predict outcomes of pleural empyema, regardless of patient’s history of COVID-19, i. e. a decrease in the lymphocyte count below 1.2×10⁹ in 1 L is associated with fatal outcome. Monocyte count carries prognostic information for cases of pleural empyema without previous COVID-19 infection. As for the relative indicators, SIRI, SII and NLR values measured on Day 1 in the hospital were predictors of ASLD outcome only in patients after COVID-19 infection, i. e., higher values were associated with increased risk of death, with NLR index being the most informative. Overall severity of illness above 10 scores by CIRS was associated with an unfavorable ASLD outcome, regardless of patient’s history of COVID-19.
Reference61 articles.
1. Korymasov E. A., Yablonskii P. K., Zhestkov K. G., Sokolovich E. G., Motus I.Ya., Lishenko V. V., Skryabin S. A. Suppurative lung diseases: national clinical guidelines of the Association of Thoracic Surgeons of Russia. Available at: http://thoracic.ru/ wp-content/uploads/НКР-по-лечению-нагноительных-заболеванийлегких-_ПРОЕКТ_pdf (accessed 28.05.2023). (In Russ.).
2. Garvia V, Paul M. Empyema. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. PMID: 29083780.
3. Stüben B. O., Plitzko G. A., Reeh M. Melling N., Izbicki J. R., Bachmann K., Tachezy M. Intrathoracic vacuum therapy for the therapy of pleural empyema-a systematic review and analysis of the literature. J Thorac Dis. 2023; 15 (2): 780–790. DOI: 10.21037/jtd-22-1188. PMID: 36910103.
4. Hassan M., Patel S., Sadaka A. S., Bedawi E. O., Corcoran J. P., Porcel J. M. Recent insights into the management of pleural infection. Int J Gen Med. 2021; 14: 3415–3429. DOI: 10.2147/IJGM.S292705. PMID: 34290522.
5. Iguina M. M., Danckers M. Thoracic empyema. In: StatPearls. Treasure Island (FL): StatPearls Publishing; February 5, 2023.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献